THE 60-SECOND GUIDE
Thymosin alpha-1
Controlled human trials · results vary by indication.
Guide prepared November 13, 2026 · profile review dates retained
What is it?
Thymosin alpha-1 is an immune-modulating peptide investigated in several disease settings. It has a clinical research record, but changing immune markers does not guarantee better survival, and results must be assessed separately for each condition. [1]
Potential benefits
Has immune-modulating activity and medical use in some countries. Studied across infectious, immune, and cancer settings. [1]
Evidence & its limits
In TESTS, published in 2025, 28-day mortality was 23.4% with thymosin alpha-1 and 24.1% with placebo, without a statistically significant difference. The published correction does not change that conclusion. This result concerns sepsis and neither proves nor disproves benefit for every other indication. [1]
Risks & unknowns
Not FDA-approved in the United States. Benefits and risks must be judged by indication and product quality. [1]
Status & scope
Not FDA-approved in the United States. [1]
The question to ask
Does the evidence match the exact product, route, condition and outcome being discussed? Check the full record and its review dates. This summary is selective; the product label and clinical assessment contain additional warnings and contraindications.
CHECK THE RECORD
Sources & review
- Full evidence record, references and review dates
- Isolation and sequence analysis, 1977
- TESTS randomized phase III trial, 2025
- Published TESTS correction, May 2025
Guide prepared November 13, 2026 · profile review dates retained. Condensed from the linked site evidence record. This format update is not a new clinical review of every source. Consult the full profile for its evidence-review dates and targeted updates.
Selective educational summary, not treatment or dosing advice. Existing profile review dates retained; no independent clinical review.